Amrutanjan Health Care is a 132-year-old Indian business that began with a single yellow pain balm and has since turned that trust into a multi-category consumer-health house - it now sells everything from headache roll-ons to sanitary pads and rehydration drinks, all under the same promise of accessible, affordable relief. The company was founded in 1893 and incorporated in 1936 in Chennai, where it is still headquartered, and it operates with no subsidiaries or joint ventures - it is a standalone, debt-free entity run by the founding family. The recurring approach is to take a mass-market health need, apply a blend of Ayurveda and modern science, and then push the product deep into India through low price points and wide distribution - first with the balm, then with a congestion inhaler, then with sanitary napkins for rural women, and most recently with rehydration beverages and personal-care items like razors.
Business segments
Four engines at different stages - a pain-relief cash cow that still commands the market, a fast-growing women's wellness platform, a small congestion-relief franchise, and a rehydration bet that is still finding its feet - each built on the distribution and trust of the one before.
1. Pain management: the balm that built the house
A 73% market share in roll-ons and a ₹2 sachet unchanged for decades make this the company's profit engine and the reason its brand is known in every Indian pharmacy.
- The original product, still the core - the yellow balm for headaches and body aches, launched over a century ago, remains the top revenue contributor, with the 8 ml yellow and white balm pack leading sales. The headache category alone brought in 57.6% of total domestic revenue in FY25.
- Pioneered the roll-on format - the company was first to put pain relief in a roll-on, and it now holds 73% of the roll-on market (as of March 2024), which is roughly three times the share of its nearest competitor. The body-ache range includes a Back Pain Roll On and a stronger Maha Strong variant.
- Price as a moat - the company sells a pain balm sachet at ₹2, a price it has deliberately kept unchanged to stay affordable for budget-conscious buyers, making it hard for rivals to undercut without losing money. Balm penetration in India is still only 37.5%, so the addressable market has plenty of room to grow.
- A hospital that builds credibility - the company runs a NABH-certified Advanced Pain Management Centre in Chennai that has treated over 15,000 chronic-pain patients using non-surgical methods like stem-cell tissue regeneration and radio-frequency neuromodulation. This clinic doubles as a research lab and a trust-builder for the brand.
- Moving into clinical-grade relief - in FY26 it launched an Advanced Ortho Pain Relief + Oil, a 100% Ayurvedic formulation clinically proven to reduce osteoarthritis and rheumatoid arthritis pain by 66% in eight weeks, using Gandhapura and Capsaicin. This stretches the brand from everyday headaches into chronic joint care.
2. Women's hygiene and personal care: the second ₹100-crore brand
Comfy sanitary napkins reached the ₹100-crore revenue mark in FY24 by targeting rural women who still use cloth, and the brand is now expanding into tampons, menstrual cups, period-pain relief and razors under a broader women's-wellness umbrella.
- Rural-first distribution - 60% of Comfy's outlet reach is in rural areas, where sanitary-napkin penetration is only 46%. The brand reaches roughly 5 lakh outlets and starts at ₹20 a pack, directly aimed at converting cloth users to modern hygiene products.
- Beyond pads - the Comfy range now includes tampons with an 8-hour leak lock, reusable menstrual cups made of medical-grade silicone, and a period-pain relief roll-on that is 100% Ayurvedic and priced at ₹135. In Q4 FY26 the brand added women's razors and antiseptic plaster, and the segment was renamed to "Women's Hygiene & Personal Care".
- Education as distribution - the company runs Project Disha, a programme that educates women about menstrual care across multiple states, and a school-based sampling programme that puts products directly into the hands of potential first-time buyers. A TV campaign featuring actress Shraddha Kapoor supports brand awareness.
3. Congestion relief: the small but steady companion brand
The Relief inhaler is the second-most-used nasal inhaler in India, and the brand has quietly expanded into rubs, cough syrup, lozenges and a nasal spray - a compact portfolio that rides on the same pharmacy shelf space as the pain balm.
- Inhaler leads the range - the Amrutanjan Relief Inhaler holds the number-two position in the nasal-inhaler category, and the portfolio also includes a chest rub, a mint lozenge in three flavours, and an Ayurvedic hot-drink powder for sore throats priced at ₹10.
- Recent line extension - in FY26 the company launched a Relief Nasal Spray, an Oxymetazoline Hydrochloride solution for adults, adding a modern format to a category traditionally dominated by inhalers and rubs. Brand Relief grossed ₹19 crore in FY26.
4. Rehydration: the everyday-health bet
Electro+ is a ready-to-drink electrolyte beverage with real fruit juice and Vitamin C, positioned not just for diarrhoea recovery but as an all-day hydration drink - a small business today that the company is backing with a dedicated, upgraded plant.
- From medical to lifestyle - the product contains electrolytes, glucose and Vitamin C, with each 200 ml bottle providing half the daily Vitamin C requirement, and it is marketed as an "All Day Rehydration" solution for active lifestyles rather than only for illness. Low-sugar variants match WHO-recommended osmolarity levels.
- Own manufacturing - the beverage plant on the outskirts of Chennai runs under FSSAI and ISO 22000 standards, with its own quality-control and microbiology lab, and has been upgraded with a 400 bottles-per-minute line that doubled capacity. The brand grossed ₹35.6 crore in FY26 and has served as the official rehydration partner of India's professional golf tour.
Group structure and partners
Amrutanjan is a standalone, debt-free company with no subsidiaries, controlled by the founding family through a holding company and run by a board where independent directors outnumber promoters.
- No subsidiaries, no debt - the company has no subsidiary, associate or joint venture, and carries no borrowings from any bank or financial institution. An employee stock option trust holds a negligible 0.04% of equity.
- Family control via a holding company - the promoter entity, GoodHealth Holdings, was converted from a partnership into a private limited company in January 2024, and the 20.15% stake previously held by the Chairman in his capacity as partner was transferred to the new company with no consideration paid. After a buyback in August 2023, promoter shareholding rose to 50.59%.
- Board composition - the seven-member board includes four independent directors (one of them a woman), two promoter-category directors, and one non-executive non-independent director. The company maintains a long-term settlement with its employees' union, signed in October 2021.